The House of Commons Health Committee is to investigate what the UK’s exit from the European Union will mean for medical R&D, as part of an inquiry into post-Brexit arrangements for the supply and regulation of medicine.
The committee will examine how Brexit could affect the development of novel medicines and technologies, and ask how any adverse consequences can be avoided or mitigated.
In an announcement on 21 September, the committee said that Brexit presents “major implications for the future of medical research and development”.
This article is only available to Research Professional News subscribers or Pivot-RP users.
If you are a Research Professional News subscriber you can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.